These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30748089)

  • 1. Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.
    Bouatou Y; Viglietti D; Pievani D; Louis K; Duong Van Huyen JP; Rabant M; Aubert O; Taupin JL; Glotz D; Legendre C; Loupy A; Lefaucheur C
    Am J Transplant; 2019 Jul; 19(7):1972-1988. PubMed ID: 30748089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.
    Lefaucheur C; Gosset C; Rabant M; Viglietti D; Verine J; Aubert O; Louis K; Glotz D; Legendre C; Duong Van Huyen JP; Loupy A
    Am J Transplant; 2018 Feb; 18(2):377-390. PubMed ID: 29086461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical and pathological significance of borderline T cell-mediated rejection.
    Nankivell BJ; Agrawal N; Sharma A; Taverniti A; P'Ng CH; Shingde M; Wong G; Chapman JR
    Am J Transplant; 2019 May; 19(5):1452-1463. PubMed ID: 30501008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
    Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
    Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients.
    Wehmeier C; Hönger G; Cun H; Amico P; Hirt-Minkowski P; Georgalis A; Hopfer H; Dickenmann M; Steiger J; Schaub S
    Am J Transplant; 2017 Aug; 17(8):2092-2102. PubMed ID: 28245084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular diagnosis of antibody-mediated rejection: Evaluating biopsy-based transcript diagnostics in the presence of donor-specific antibodies but without microvascular inflammation, a single-center descriptive analysis.
    Harmacek D; Weidmann L; Castrezana Lopez K; Schmid N; Korach R; Bortel N; von Moos S; Rho E; Helmchen B; Gaspert A; Schachtner T
    Am J Transplant; 2024 Sep; 24(9):1652-1663. PubMed ID: 38548057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.
    Viglietti D; Bouatou Y; Kheav VD; Aubert O; Suberbielle-Boissel C; Glotz D; Legendre C; Taupin JL; Zeevi A; Loupy A; Lefaucheur C
    Kidney Int; 2018 Oct; 94(4):773-787. PubMed ID: 29801667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
    Loupy A; Vernerey D; Tinel C; Aubert O; Duong van Huyen JP; Rabant M; Verine J; Nochy D; Empana JP; Martinez F; Glotz D; Jouven X; Legendre C; Lefaucheur C
    J Am Soc Nephrol; 2015 Jul; 26(7):1721-31. PubMed ID: 25556173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.
    Senev A; Coemans M; Lerut E; Van Sandt V; Daniëls L; Kuypers D; Sprangers B; Emonds MP; Naesens M
    Am J Transplant; 2019 Mar; 19(3):763-780. PubMed ID: 30107078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rejection of the Renal Allograft in the Absence of Demonstrable Antibody and Complement.
    Zhao X; Huang G; Randhawa S; Zeng G; Lunz J; Randhawa P
    Transplantation; 2017 Feb; 101(2):395-401. PubMed ID: 26901079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
    Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
    Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
    Luque S; Lúcia M; Melilli E; Lefaucheur C; Crespo M; Loupy A; Bernal-Casas D; Gomà M; Jarque M; Crespo E; Montero N; Manonelles A; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
    Am J Transplant; 2019 Feb; 19(2):368-380. PubMed ID: 30085394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.
    Cherukuri A; Mehta R; Sharma A; Sood P; Zeevi A; Tevar AD; Rothstein DM; Hariharan S
    Kidney Int; 2019 Jul; 96(1):202-213. PubMed ID: 31029504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell Mediated Rejection Associated Microvascular Inflammation in the Allograft Kidney: RNAseq Analysis Using the Banff Human Organ Transplant Gene Panel.
    Barwad A; Huang Y; Randhawa P
    Clin Transplant; 2024 Jul; 38(7):e15410. PubMed ID: 39033507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury.
    Zhao D; Li S; Liao T; Wei Y; Liu M; Han F; Luo Z; Liu X; Sun Q
    Am J Transplant; 2018 May; 18(5):1083-1095. PubMed ID: 29178433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion.
    Nankivell BJ; Shingde M; Keung KL; Fung CL; Borrows RJ; O'Connell PJ; Chapman JR
    Am J Transplant; 2018 Feb; 18(2):364-376. PubMed ID: 29194971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.